GCP
MBIO icon

GSA Capital Partners’s Mustang Bio MBIO Stock Holding History

GSA Capital Partners’s Portfolio MBIO Stock Details MBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,834
Closed -$13K – 1987
2025
Q4 		$13K Buy
+12,834
New +$16.9K ﹤0.01% 1614
2023
Q1 		– Sell
-535
Closed -$158K – 1751
2022
Q4 		$158K Sell
535
-768
-59% -$262K 0.02% 1238
2022
Q3 		$459K Buy
1,303
+76
+6% +$35.2K 0.06% 633
2022
Q2 		$539K Sell
1,227
-395
-24% -$219K 0.08% 451
2022
Q1 		$1.23M Sell
1,622
-136
-8% -$112K 0.17% 117
2021
Q4 		$2.19M Buy
1,758
+1,011
+135% +$1.63M 0.28% 18
2021
Q3 		$1.51M Buy
747
+403
+117% +$866K 0.15% 129
2021
Q2 		$857K Buy
344
+24
+8% +$58.8K 0.1% 325
2021
Q1 		$796K Buy
320
+66
+26% +$196K 0.13% 180
2020
Q4 		$722K Buy
254
+54
+27% +$129K 0.12% 237
2020
Q3 		$473K Buy
200
+144
+257% +$355K 0.08% 424
2020
Q2 		$135K Buy
56
+1
+2% +$2.34K 0.08% 437
2020
Q1 		$111K Buy
+55
New +$141K 0.03% 880

Other funds holding MBIO

KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

GSA Capital Partners's MBIO Position: Q1 2026 in Review

GSA Capital Partners sold out of Mustang Bio (MBIO) in Q1 2026, closing a stake of 12,834 shares — an estimated $13K sold.

GSA Capital Partners first reported a position in MBIO in Q1 2020 and held it in 13 quarters. The position peaked at $2.19M in Q4 2021. 22 funds tracked by Wall St. Rank hold MBIO as of Q1 2026.

  • GSA Capital Partners reported no remaining Mustang Bio position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 12,834 Mustang Bio shares in Q1 2026, an estimated $13K.
  • GSA Capital Partners first reported a position in Mustang Bio in Q1 2020 and held it in 13 quarters.
  • GSA Capital Partners's Mustang Bio position peaked at $2.19M in Q4 2021.
  • 22 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.